Peptide Agonists of Prostate-Specific Antigen and Uses Thereof
Description of Invention:
Current treatment for prostate cancer involves surgery, radiation, chemotherapy, and/or hormonal therapy. In spite of these treatments, over 40,000 men die of prostate cancer each year in the United States alone. A promising new treatment modality for prostate cancer involves harnessing the body’s own immune response to eliminate a cancer. Traditional and non-traditional vaccine therapies have been shown to stimulate an immune response against commonly expressed tumor-associated antigens. One such common tumor-associated antigen expressed on a majority of prostate cancer cells is Prostate Specific Antigen (PSA).
The present invention relates to isolated peptides comprising immunogenic peptides derived from PSA. These immunogenic peptides are considered agonist epitopes of the wild-type PSA-3 cytotoxic T lymphocyte (CTL) epitope: an agonist epitope is modified from the wild type epitope and shows greater immune stimulating characteristics. This invention claims the physical composition and use of the PSA-3 agonist epitopes, including peptide, nucleic acid, pharmaceutical composition, and method of treatment. The PSA-3 agonist epitopes would have application in a number of traditional and non-traditional vaccine delivery systems for the treatment of cancer.
Inventors:
Kwong-yok Tsang and Jeffrey Schlom (NCI)
Patent Status:
DHHS Reference No. E-123-2001/0-US-01 filed 30 Nov 2001 (U.S. Provisional Application No. 60/334,575)
DHHS Reference No. E-124-2001/1-PCT-01 filed 26 Nov 2003 (PCT Application No. PCT/US02/37805) and subsequent National Stage filings in the United States, Europe, Canada, Australia, and Japan
Relevant Publication:
This invention has been published in Schlom, et al., “Identification and Characterization of a Human Agonist Cytotoxic T-Lymphocyte Epitope of Human Prostate-specific Antigen.” Clinical Cancer Research, Vol. 8, 41-53, January 2002.
Licensing Status:
Some vaccine delivery fields of use for the PSA-3 epitope have been exclusively licensed. However, a number of fields are available for other traditional and non-traditional vaccine delivery systems.
In addition to licensing, the technology is available for further development through collaborative research with the inventors via a Cooperative Research and Development Agreement (CRADA).
Portfolios: Cancer
Cancer -Diagnostics-In Vitro-MAb Based Cancer -Diagnostics-In Vitro-Other Cancer -Diagnostics Cancer -Therapeutics Cancer -Research Materials
For Additional Information Please Contact: Michelle A. Booden Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: (301)451-7337
Email: boodenm@mail.nih.gov
Fax: (301) 402-0220
